These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31560095)

  • 1. Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis.
    Macaron G; Feng J; Moodley M; Rensel M
    Curr Treat Options Neurol; 2019 Sep; 21(10):50. PubMed ID: 31560095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.
    Jakimovski D; Awan S; Eckert SP; Farooq O; Weinstock-Guttman B
    CNS Drugs; 2022 Jan; 36(1):45-59. PubMed ID: 34940954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Aggressive Treatment Approaches for Multiple Sclerosis.
    Simpson A; Mowry EM; Newsome SD
    Curr Treat Options Neurol; 2021; 23(7):19. PubMed ID: 34025110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data.
    Gontika M; Skarlis C; Markoglou N; Evangelopoulos ME; Velonakis G; Chrousos GP; Dalakas M; Stefanis L; Anagnostouli M
    Neurol Sci; 2022 Apr; 43(4):2641-2649. PubMed ID: 34596776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of Newer Disease Modifying Therapies in Multiple Sclerosis.
    Jalkh G; Abi Nahed R; Macaron G; Rensel M
    Vaccines (Basel); 2020 Dec; 9(1):. PubMed ID: 33375365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis.
    McKay KA; Manouchehrinia A; Berrigan L; Fisk JD; Olsson T; Hillert J
    JAMA Neurol; 2019 Sep; 76(9):1028-1034. PubMed ID: 31206130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities.
    Margoni M; Rinaldi F; Perini P; Gallo P
    Front Neurol; 2021; 12():676095. PubMed ID: 34079516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Treatment Strategies of Pediatric Multiple Sclerosis, Including the use of Disease Modifying Therapies.
    Rensel M
    Children (Basel); 2019 May; 6(6):. PubMed ID: 31159312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on pediatric-onset multiple sclerosis.
    Ruet A
    Rev Neurol (Paris); 2018 Jun; 174(6):398-407. PubMed ID: 29784250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis.
    McGinley M; Rossman IT
    Neurotherapeutics; 2017 Oct; 14(4):985-998. PubMed ID: 28895071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of quality of life in pediatric- and adult-onset multiple sclerosis.
    McKay KA; Ernstsson O; Manouchehrinia A; Olsson T; Hillert J
    Neurology; 2020 Mar; 94(9):e932-e941. PubMed ID: 31732567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review Of The Safety, Efficacy And Tolerability Of Fingolimod In The Treatment Of Pediatric Patients With Relapsing-Remitting Forms Of Multiple Sclerosis (RRMS).
    Feng J; Rensel M
    Pediatric Health Med Ther; 2019; 10():141-146. PubMed ID: 31814792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Li H; Hu F; Zhang Y; Li K
    J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.
    Krysko KM; Graves JS; Rensel M; Weinstock-Guttman B; Rutatangwa A; Aaen G; Belman A; Benson L; Chitnis T; Gorman M; Goyal MS; Harris Y; Krupp L; Lotze T; Mar S; Moodley M; Ness J; Rodriguez M; Rose J; Schreiner T; Tillema JM; Waltz M; Casper TC; Waubant E;
    Ann Neurol; 2020 Jul; 88(1):42-55. PubMed ID: 32267005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newer disease modifying treatments in pediatric onset multiple sclerosis: Experience from a single center.
    Solmaz I; Acar Ozen P; Parlak S; Tuncer A; Anlar B
    Eur J Paediatr Neurol; 2022 Jul; 39():110-115. PubMed ID: 35777190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TyPed study: Natalizumab for the treatment of pediatric-onset multiple sclerosis in Portugal.
    Palavra F; Figueiroa S; Correia AS; Tapadinhas F; Cerqueira J; Guerreiro RP; de Sá J; Sá MJ; Almeida S; Mota P; Sousa L
    Mult Scler Relat Disord; 2021 Jun; 51():102865. PubMed ID: 33714125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.
    Zimmermann M; Brouwer E; Tice JA; Seidner M; Loos AM; Liu S; Chapman RH; Kumar V; Carlson JJ
    CNS Drugs; 2018 Dec; 32(12):1145-1157. PubMed ID: 30141001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.
    Baroncini D; Simone M; Iaffaldano P; Brescia Morra V; Lanzillo R; Filippi M; Romeo M; Patti F; Chisari CG; Cocco E; Fenu G; Salemi G; Ragonese P; Inglese M; Cellerino M; Margari L; Comi G; Zaffaroni M; Ghezzi A;
    JAMA Neurol; 2021 Jun; 78(6):726-735. PubMed ID: 33938921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.